A cough suppressant and a drug tested as a schizophrenia therapy curb the involuntary movements that are disabling side effects of taking the Parkinson's disease medication levodopa, Portland scientists have found.
Dextromethorphan, used in such cold and flu medications as Robitussin, Sucrets, Triaminic and Vicks, suppresses dyskinesias in rats, researchers at Oregon Health & Science University and the Portland Veterans Affairs Medical Center found. Dyskinesias are the spastic or repetitive motions that result from taking levodopa, or L-dopa, over long periods.
The researchers also found that BMY-14802, a drug previously tested in people with schizophrenia and found to be safe – although not effective in treating schizophrenia symptoms – suppressed dyskinesias in rats more effectively than dextromethorphan did, suggesting that BMY-14802 might work to block dyskinesias in people with Parkinson's.
"These results were unexpected, but very exciting," said the study's lead author, Melanie A. Paquette, Ph.D., postdoctoral fellow in the Department of Behavioral Neuroscience, OHSU School of Medicine, and the PVAMC. "We have filed a patent for the use of BMY-14802 for dyskinesias and we hope to get funding to begin human trials very soon."
The study, titled "Differential effects of NMDA antagonists and sigma ligands on L-dopa-induced behavior in the hemiparkinson rat," is being presented during a poster session today at Neuroscience 2007, the 37th annual Society for Neuroscience conference in San Diego.
The results also affirm the value of the rat model for dyskinesias that Paquette's team used in the study. Previous studies by other researchers have shown the drug amantadine already is effective in treating dyskinesias in both humans and rats, and dextromethorphan's effectiveness against the condition in rats provides more data supporting the use of the model.
"Basically, these two drugs work to block dyskinesias in both humans and rats, and that means the rats are a good model to screen potential drug treatments for humans with dyskinesias," Paquette said.
But BMY-14802, which is an antagonist at sigma-1 receptor sites in the brain, "worked much better than dextromethorphan," an antagonist at N-methyl-D-aspartate (NMDA) receptors.
"There's something special about BMY-14802," Paquette explained. "The effect on dyskinesias is really striking and I've repeated it several times, so it's a reliable finding. It's a very exciting result."
Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania
The strange double life of Dab2
10.01.2017 | University of Miami Miller School of Medicine
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).
Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...
Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.
The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...
10.01.2017 | Event News
09.01.2017 | Event News
05.01.2017 | Event News
17.01.2017 | Earth Sciences
17.01.2017 | Materials Sciences
17.01.2017 | Architecture and Construction